Loading…
Sana Biotechnology, Inc. is projected to rise to $3.49 by 2027, a +11% move from its current price of $3.13. SANA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $3.03 | $3.13 | $3.23 | 0.00% |
| Aug 3 | $2.99 | $3.13 | $3.27 | 0.00% |
| Aug 4 | $2.96 | $3.13 | $3.31 | 0.00% |
| Aug 5 | $2.94 | $3.13 | $3.33 | -0.01% |
| Aug 6 | $2.92 | $3.13 | $3.36 | -0.01% |
| Aug 7 | $2.90 | $3.13 | $3.38 | -0.01% |
| Aug 8 | $2.88 | $3.13 | $3.40 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.88 | $3.13 | $3.40 | -0.01% |
| Week 2 | $2.78 | $3.13 | $3.52 | -0.02% |
| Week 3 | $2.71 | $3.13 | $3.62 | -0.03% |
| Week 4 | $2.65 | $3.13 | $3.70 | -0.04% |
| Week 5 | $2.60 | $3.13 | $3.77 | -0.05% |
| Week 6 | $2.55 | $3.13 | $3.84 | -0.06% |
| Week 7 | $2.51 | $3.13 | $3.90 | -0.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sana Biotechnology, Inc. is a biotechnology company focused on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc.
in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Sana Biotechnology, Inc. trades under the symbol SANA and currently shows a price of $3.17 with a market capitalization of $882.18M. Its market rank is 2591. The stock’s near-term price trajectory combines a bearish technical backdrop with a defined support of $2.68 and resistance at $4.12, while the 30-day trading range extends from $2.44 to $4.12.
The current price context sits amid an elevated annualized volatility of 80%.
A major floor 21.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.3% away) — a key level to hold.
The nearest ceiling, 31.6% above — a clean break opens room to run.
A major ceiling 42.4% above — clearing it would confirm fresh momentum.
Key SANA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SANA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.22 | Sell | $3.20 | Sell |
| MA 10 | $3.19 | Sell | $3.24 | Sell |
| MA 20 | $3.44 | Sell | $3.31 | Sell |
| MA 50 | $3.26 | Sell | $3.32 | Sell |
| MA 100 | $3.25 | Sell | $3.40 | Sell |
| MA 200 | $3.83 | Sell | $3.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.08 | Neutral |
| Stoch RSI (14) | 19.78 | Buy |
| CCI (20) | -68.06 | Neutral |
| Williams %R (14) | -97.78 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -11.83 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 2.22 | Buy |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 43.33 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 3.21 | Sell |
| ADX (14) | 17.65 | Neutral |
| ATR (14) | 0.09 | Info |
In the near term, sentiment is bearish with RSI(14) at 40. The stock trades around the 50-day moving average at $3.28 and below the 200-day moving average at $3.88, signaling internal weakness. Support sits at $2.68 and resistance at $4.12, framing a 30-day range of $2.44 to $4.12.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.68 | $3.13 | $3.97 | 0% | Neutral | |
| $2.74 | $3.49 | $4.71 | +11% | Neutral | |
| $2.63 | $3.46 | $4.88 | +11% | Neutral | |
| $2.43 | $3.29 | $4.79 | +5% | Neutral | |
| $2.78 | $3.85 | $5.76 | +23% | Bullish | |
| $3.06 | $4.33 | $6.65 | +38% | Bullish | |
| $3.44 | $4.97 | $7.79 | +59% | Bullish | |
| $3.79 | $5.59 | $8.93 | +79% | Bullish | |
| $3.57 | $5.36 | $8.72 | +71% | Bullish | |
| $3.72 | $5.69 | $9.41 | +82% | Bullish | |
| $5.05 | $8.37 | $14.81 | +167% | Bullish | |
| $6.93 | $13.25 | $25.89 | +323% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.68 | $3.13 | $3.68 | +0.00% |
| September 2026 | $2.62 | $3.11 | $3.81 | -0.60% |
| October 2026 | $2.61 | $3.13 | $3.88 | +0.46% |
| November 2026 | $2.54 | $3.06 | $3.84 | -2.00% |
| December 2026 | $2.59 | $3.14 | $3.97 | +2.53% |
Click any year to see its month-by-month SANA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sana Biotechnology, Inc.'s 2026 outlook centres on $3.13, within a $2.68 to $3.97 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SANA could reach as high as $4.71, with a base case around $3.49 and support toward $2.74 — roughly +11% from $3.13. A consolidation phase looks the most probable path here.
Expect SANA to range from $2.63 to $4.88 through 2028. The $3.46 average target implies a +11% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The SANA price prediction for 2029 points to an average of $3.29 (low $2.43, high $4.79) — a potential gain of +5% on today's $3.13. A consolidation phase looks the most probable path here.
In 2030, SANA is projected to trade between $2.78 and $5.76, averaging $3.85 — a potential gain of +23% from today's $3.13. That is up +17% on the projected 2029 average. Momentum favours further upside here.
Sana Biotechnology, Inc.'s 2031 outlook centres on $4.33, within a $3.06 to $6.65 range. That is up +13% on the projected 2030 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SANA could reach as high as $7.79, with a base case around $4.97 and support toward $3.44 — roughly +59% from $3.13. Momentum favours further upside here.
Expect SANA to range from $3.79 to $8.93 through 2033. The $5.59 average target implies a +79% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SANA price prediction for 2034 points to an average of $5.36 (low $3.57, high $8.72) — a potential gain of +71% on today's $3.13. Momentum favours further upside here.
In 2035, SANA is projected to trade between $3.72 and $9.41, averaging $5.69 — a potential gain of +82% from today's $3.13. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sana Biotechnology, Inc.'s 2040 outlook centres on $8.37, within a $5.05 to $14.81 range. That is up +47% on the projected 2035 average. That marks a +167% change versus current levels. Momentum favours further upside here.
By 2050, SANA could reach as high as $25.89, with a base case around $13.25 and support toward $6.93 — roughly +323% from $3.13. Buyers look set to stay in control over this stretch.
Investing $1,000 in SANA today (≈ 319.488818 SANA) could be worth
$4,233.3
+$3,233.3 (+323%) by 2050 · US Dollar
Based on the average projected SANA price of $13.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SANAwould be worth at today's price.
$1,000 invested in SANA on Jul 31, 2025 (≈ 246.305422 SANA) would be worth
$770.94
-$229.06 (-22.9%) today · 0.77× · US Dollar
Based on a SANA entry price of $4.06 vs. today's $3.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.18 | $984.28 | -1.6% |
| 1 month ago | $3.56 | $879.21 | -12.1% |
| 3 months ago | $3.27 | $957.19 | -4.3% |
| 6 months ago | $4.59 | $681.92 | -31.8% |
| 1 year ago | $4.06 | $770.94 | -22.9% |
| All time (5.0y) ago | $16.55 | $189.12 | -81.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SANA forecast.
Our base-case forecast reaches $6.30 around 2040.
Implied market cap at $6.30: $1.75B
The multi-year forecast shows a neutral stance in 2026 with an average price of $3.17 and a range of $2.68 to $4.23. From 2031 onward the outlook turns bullish, with the average price rising to $4.36 in 2031 and up to $13.50 on average by 2050, while the maximum forecast peaks at $29.16. Notably, the forecast implies a 19.3% return in 2030, then accelerating to 37.6% in 2031, 62.1% in 2032, 79.8% in 2033, 70.1% in 2034, 82.9% in 2035, 165% in 2040, and 325.7% by 2050.
The longer-horizon bullish trajectory is accompanied by meaningful upside potential but remains subject to the uncertainties inherent in equity investing.
Tap a question to reveal the answer.
In 2030, the forecast shows min $2.58, avg $3.78, max $6.00 with ROI 19.3 and neutral sentiment.
Forecasts indicate neutral sentiment through 2026-2030, then bullish from 2031 onward, with the average price rising to $13.50 by 2050 and a max of $29.16. These are estimates and carry risks; not guarantees.
Yes. The 2035 forecast shows min $3.46, avg $5.80, max $10.33 with ROI 82.9 and bullish sentiment, suggesting crossing $10 is possible within the projection.
For 2032, the forecast is min $3.31, avg $5.14, max $8.60 with ROI 62.1 and bullish sentiment.
In 2050, the forecast shows min $6.07, avg $13.50, max $29.16 with ROI 325.7 and bullish sentiment.
Sana Biotechnology, Inc. Community Discussion
0Share your Sana Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.